Femasys, Inc. (FEMY)
NASDAQ:FEMY
Top Page
Femasys
(NASDAQ:FEMY)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.38
▼(-48.49% Downside)
Action:ReiteratedDate:04/02/26
The score is primarily constrained by weak financial performance—persistent losses, deeply negative cash generation, and limited evidence of near-term self-funding—despite improved leverage. Technicals also remain bearish with the stock below major moving averages and a negative MACD, while valuation support is limited by negative earnings. Corporate events are mixed, with an execution-positive COO hire offset by ongoing Nasdaq compliance risk.
Positive Factors
Operational leadership
Hiring a veteran medical-device operations executive with global commercialization experience strengthens Femasys’ ability to scale clinical adoption and manufacturing cadence. This improves execution risk, supply chain oversight and commercialization capabilities, supporting sustainable revenue growth as products move from development to broader clinical rollout.
Negative Factors
Persistent cash burn
Material and persistent negative operating and free cash flow implies ongoing external funding needs. Over the medium term this creates dilution risk, constrains investment in commercial expansion, and pressures management to prioritize near-term financing over strategic product or geographic investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Operational leadership
Hiring a veteran medical-device operations executive with global commercialization experience strengthens Femasys’ ability to scale clinical adoption and manufacturing cadence. This improves execution risk, supply chain oversight and commercialization capabilities, supporting sustainable revenue growth as products move from development to broader clinical rollout.
Read all positive factors
Femasys (FEMY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$23.72M
Dividend YieldN/A
Average Volume (3M)585.86K
Price to Earnings (P/E)―
Beta (1Y)0.72
Revenue Growth63.53%
EPS Growth12.49%
CountryUS
Employees69
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.02
Shares Outstanding60,390,686
10 Day Avg. Volume704,618
30 Day Avg. Volume585,857
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.88
Price to Sales (P/S)9.94
P/FCF Ratio-1.19
Enterprise Value/Market Cap0.30
Enterprise Value/Revenue3.12
Enterprise Value/Gross Profit5.03
Enterprise Value/Ebitda-0.45
Forecast
1Y Price Target
$1.50Price Target Upside105.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.38
Revenue Forecast (FY)$6.51M
Femasys Business Overview & Revenue Model
Company Description
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy de...
How the Company Makes Money
Femasys makes money primarily by selling its women’s health medical devices and related consumables to healthcare providers and facilities, generating product revenue as units are purchased and used in clinical settings. Revenue is also supported ...
Femasys Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
16
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.29M | 1.63M | 1.07M | 1.21M | 1.18M |
| Gross Profit | 1.42M | 1.08M | 691.90K | 764.28K | 809.30K |
| EBITDA | -15.89M | -16.33M | -13.17M | -10.49M | -6.55M |
| Net Income | -18.63M | -18.82M | -14.25M | -11.39M | -7.54M |
Balance Sheet | |||||
| Total Assets | 20.72M | 12.45M | 27.76M | 16.90M | 28.58M |
| Cash, Cash Equivalents and Short-Term Investments | 9.27M | 3.45M | 21.72M | 12.96M | 24.78M |
| Total Debt | 4.70M | 7.44M | 6.70M | 543.72K | 990.21K |
| Total Liabilities | 14.85M | 10.14M | 9.40M | 1.65M | 2.24M |
| Stockholders Equity | 5.87M | 2.30M | 18.35M | 15.24M | 26.33M |
Cash Flow | |||||
| Free Cash Flow | -19.22M | -20.21M | -11.42M | -11.14M | -8.24M |
| Operating Cash Flow | -18.69M | -19.44M | -11.28M | -10.73M | -7.93M |
| Investing Cash Flow | -630.10K | -847.76K | -143.92K | -407.48K | -306.87K |
| Financing Cash Flow | 25.14M | 2.03M | 20.18M | -681.64K | 29.70M |
Femasys Technical Analysis
Negative
0.73
Price Trends
0.52
Negative
0.65
Negative
0.66
Negative
Market Momentum
-0.04
Positive
33.02
Neutral
42.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FEMY, the sentiment is Negative. The current price of 0.73 is above the 20-day moving average (MA) of 0.51, above the 50-day MA of 0.52, and above the 200-day MA of 0.66, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 33.02 is Neutral, neither overbought nor oversold. The STOCH value of 42.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FEMY.
Femasys Risk Analysis
Femasys disclosed 75 risk factors in its most recent earnings report. Femasys reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Femasys Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $22.69M | -3.92 | -164.78% | ― | 0.59% | -39.76% | |
45 Neutral | $42.62M | -4.53 | -60.56% | ― | 13.67% | -37.01% | |
45 Neutral | $6.76M | -4.22 | -55.33% | ― | 73.38% | 34.87% | |
43 Neutral | $20.69M | -1.84 | -8.13% | ― | -0.95% | 58.17% | |
42 Neutral | $23.72M | -1.22 | -534.91% | ― | 63.53% | 12.49% |
* Healthcare Sector Average
FEMY
Femasys
0.39
-0.79
-66.78%
RVP
Retractable Technologies
0.69
>-0.01
-1.29%
MLSS
Milestone Scientific
0.28
-0.67
-70.38%
POCI
Precision Optics Corporation
3.90
-0.30
-7.14%
NXGL
NexGel Inc
0.61
-2.05
-77.03%
Femasys Corporate Events
Business Operations and StrategyExecutive/Board Changes
Femasys Names John Canning as New Chief Operating Officer
Positive
Apr 1, 2026
On April 1, 2026, Femasys Inc. announced it had appointed veteran medical device executive John Canning as chief operating officer, effective March 30, 2026, as the company scales commercialization of its fertility and permanent birth control port...
Executive/Board ChangesPrivate Placements and Financing
Femasys Amends Financing Terms and Issues New Warrants
Neutral
Mar 20, 2026
Femasys Inc. amended its November 3, 2025 Securities Purchase Agreement with certain lenders on March 19, 2026, removing the share combination event adjustment from its senior secured convertible notes and associated warrants effective December 31...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Femasys Receives Nasdaq Extension to Regain Listing Compliance
Negative
Jan 15, 2026
On July 16, 2025, Femasys Inc. was notified by Nasdaq that its common stock had failed to meet the $1.00 per share minimum bid price requirement for 30 consecutive business days, triggering a potential delisting process. The company initially had ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.